Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 5, 2013, Pages 1893-1898

  Marzi, Andrea ^a   Engelmann, Flora ^b   Feldmann, Friederike ^c   Haberthur, Kristen ^b   Shupert, W Lesley ^a   Brining, Douglas ^c   Scott, Dana P ^c   Geisbert, Thomas W ^d   Kawaoka, Yoshihiro ^e,f   Katze, Michael G ^g   Feldmann, Heinz ^a   Messaoudi, Ilhem ^b,h  

^a Division of Intramural Research   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^e UNIVERSITY OF TOKYO   (Japan)

^f JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^g UNIVERSITY OF WASHINGTON   (United States)

^h OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; EBOLA VACCINE; IMMUNOGLOBULIN G;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIVIRAL ACTIVITY; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; EBOLA VIRUS; LETHAL DOSE; MARBURG VIRUS; NONHUMAN; PRIORITY JOURNAL; T CELL DEPLETION; VACCINATION;

ANIMALS; ANTIBODIES, VIRAL; CYTOKINES; EBOLA VACCINES; EBOLAVIRUS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HEMORRHAGIC FEVER, EBOLA; HUMANS; IMMUNOGLOBULIN G; LIVER; LYMPHOCYTES; MACACA FASCICULARIS; MALE; MARBURGVIRUS; MEMBRANE GLYCOPROTEINS; RECOMBINANT FUSION PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SPLEEN; TIME FACTORS; VESICULAR STOMATITIS INDIANA VIRUS; VIRAL ENVELOPE PROTEINS; VIRAL LOAD;

EID: 84873202509     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1209591110     Document Type: Article

References (35)

1. Sanchez A, Geisbert T, Feldmann H (2007) Filoviridae. Fields Virology, eds Knipe DM, Howley PM (Lippincott Williams & Wilkins, Philadelphia), 5th ed, Vol 1, pp 1409-1448.
2. Towner JS, et al. (2008) Newly discovered ebola virus associated with hemorrhagic fever outbreak in Uganda. PLoS Pathog 4(11):e1000212.
3. Bente D, Gren J, Strong JE, Feldmann H (2009) Disease modeling for Ebola and Marburg viruses. Dis Model Mech 2(1-2):12-17.
4. Falzarano D, Geisbert TW, Feldmann H (2011) Progress in filovirus vaccine development: Evaluating the potential for clinical use. Expert Rev Vaccines 10(1):63-77.
5. Lawson ND, Stillman EA, Whitt MA, Rose JK (1995) Recombinant vesicular stomatitis viruses from DNA. Proc Natl Acad Sci USA 92(10):4477-4481.
6. Schwartz JA, et al. (2011) Vesicular stomatitis virus-based H5N1 avian influenza vaccines induce potent cross-clade neutralizing antibodies in rhesus macaques. J Virol 85(9):4602-4605.
7. Schell J, et al. (2009) Long-term vaccine protection from AIDS and clearance of viral DNA following SHIV89.6P challenge. Vaccine 27(7):979-986.
8. Marzi A, Feldmann H, Geisbert TW, Falzarano D (2011) Vesicular stomatitis virusbased vaccines for prophylaxis and treatment of filovirus infections. J Bioterror Biodef S 1(004):2157-2526-S1-004.
9. Geisbert TW, Bausch DG, Feldmann H (2010) Prospects for immunisation against Marburg and Ebola viruses. Rev Med Virol 20(6):344-357.
10. Geisbert TW, et al. (2008) Recombinant vesicular stomatitis virus vector mediates postexposure protection against Sudan Ebola hemorrhagic fever in nonhuman primates. J Virol 82(11):5664-5668. (Pubitemid 351705275)
11. Feldmann H, et al. (2007) Effective post-exposure treatment of Ebola infection. PLoS Pathog 3(1):e2.
12. Geisbert TW, et al. (2008) Vesicular stomatitis virus-based ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates. PLoS Pathog 4(11):e1000225.
13. Ebihara H, et al. (2011) Host response dynamics following lethal infection of rhesus macaques with Zaire ebolavirus. J Infect Dis 204(Suppl 3):S991-S999.
14. Villinger F, et al. (1999) Markedly elevated levels of interferon (IFN)-gamma, IFN-alpha, interleukin (IL)-2, IL-10, and tumor necrosis factor-alpha associated with fatal Ebola virus infection. J Infect Dis 179(Suppl 1):S188-S191. (Pubitemid 29091401)
15. Aleksandrowicz P, et al. (2008) Viral haemorrhagic fever and vascular alterations. Hamostaseologie 28(1-2):77-84. (Pubitemid 351326264)
16. Reed DS, Mohamadzadeh M (2007) Status and challenges of filovirus vaccines. Vaccine 25(11):1923-1934. (Pubitemid 46227672)
17. Warfield KL, et al. (2005) Induction of humoral and CD8+ T cell responses are required for protection against lethal Ebola virus infection. J Immunol 175(2):1184-1191. (Pubitemid 41095006)
18. Sanchez A, et al. (2004) Analysis of human peripheral blood samples from fatal and nonfatal cases of Ebola (Sudan) hemorrhagic fever: Cellular responses, virus load, and nitric oxide levels. J Virol 78(19):10370-10377. (Pubitemid 39258362)
19. Jones SM, et al. (2007) Assessment of a vesicular stomatitis virus-based vaccine by use of the mouse model of Ebola virus hemorrhagic fever. J Infect Dis 196(Suppl 2):S404-S412. (Pubitemid 351417288)
20. Wong G, et al. (2012) Immune parameters correlate with protection against ebola virus infection in rodents and nonhuman primates. Sci Transl Med 4(158):158ra146.
21. Sullivan NJ, Martin JE, Graham BS, Nabel GJ (2009) Correlates of protective immunity for Ebola vaccines: Implications for regulatory approval by the animal rule. Nat Rev Microbiol 7(5):393-400.
22. Baize S, et al. (1999) Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients. Nat Med 5(4):423-426. (Pubitemid 29180581)
23. Mupapa K, et al. (1999) Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. J Infect Dis 179(Suppl 1):S18-S23. (Pubitemid 29091378)
24. Jahrling PB, et al. (1996) Passive immunization of Ebola virus-infected cynomolgus monkeys with immunoglobulin from hyperimmune horses. Arch Virol Suppl 11:135-140. (Pubitemid 126446186)
25. Parren PW, Geisbert TW, Maruyama T, Jahrling PB, Burton DR (2002) Pre-and postexposure prophylaxis of Ebola virus infection in an animal model by passive transfer of a neutralizing human antibody. J Virol 76(12):6408-6412. (Pubitemid 34556338)
26. Oswald WB, et al. (2007) Neutralizing antibody fails to impact the course of Ebola virus infection in monkeys. PLoS Pathog 3(1):e9.
27. Dye JM, et al. (2012) Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease. Proc Natl Acad Sci USA 109(13):5034-5039.
28. Qiu X, et al. (2012) Ebola GP-specific monoclonal antibodies protect mice and guinea pigs from lethal Ebola virus infection. PLoS Negl Trop Dis 6(3):e1575.
29. Marzi A, et al. (2012) Protective efficacy of neutralizing monoclonal antibodies in a nonhuman primate model of Ebola hemorrhagic fever. PLoS One 7(4):e36192.
30. Qiu X, et al. (2012) Successful treatment of Ebola virus-infected cynomolgus macaques with monoclonal antibodies. Sci Transl Med 4(138):138ra181.
31. Sullivan NJ, et al. (2011) CD8+ cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates. Nat Med 17(9):1128-1131.
32. Safronetz D, et al. (2009) Adenovirus vectors expressing hantavirus proteins protect hamsters against lethal challenge with Andes virus. J Virol 83(14):7285-7295.
33. Brown KS, Safronetz D, Marzi A, Ebihara H, Feldmann H (2011) Vesicular stomatitis virus-based vaccine protects hamsters against lethal challenge with Andes virus. J Virol 85(23):12781-12791.
34. Marzi A, et al. (2011) Vesicular stomatitis virus-based Ebola vaccines with improved cross-protective efficacy. J Infect Dis 204(Suppl 3):S1066-S1074.
35. Reynolds MR, et al. (2010) Macaques vaccinated with simian immunodeficiency virus SIVmac239Delta nef delay acquisition and control replication after repeated low-dose heterologous SIV challenge. J Virol 84(18):9190-9199.